Endocyte stock: buy or sell?

ECYT stock price: $23.99 -0.04% At close on December 20th, 2018

Updated on:
December 20th, 2018


Even the red candle ($23.99, -0.04%), Endocyte peaked new all time high at $24.00.

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States.

Should I buy Endocyte stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Currently, 2 buy setups match with Endocyte stock now:

Buy setupElegible
New all-time highYes
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MANo

Is Endocyte stock a buy?

Banks and financial institutions post stock ratings everyday. Unfortunately, we couldn't find any rating for ECYT stock for the last 30 days.

Endocyte stock analysis

Daily outlook

Despite of closing lower ($23.99, -0.04%), Endocyte marked new all time high at $24.00.

Despite of the negative close ($23.99, -0.04%), Endocyte topped new all time high at $24.00. ECYT shows a sign of strength in the short-term after finally breaking out above $23.94 on December and marking a new rising bottom. Since price and SMA100d lines crossed up , ECYT climbed $8.43 (54.18%).

ECYT stock chart (daily)

Weekly outlook

Endocyte ended this week at $23.99 after topping to a new all time high ($24.00) and appreciated a tiny 0.63%. Counting this, it's been 4 climbing weeks in a row, soaring a 1.65%.

Endocyte stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. By mid October 2018 ECYT price bounced up over the SMA of 20 weeks that acted as support stopping new slides.

ECYT stock chart (weekly)

Endocyte stock price history

Endocyte stock went public on March 5th, 2018 with a price of $6.391. Since then, ECYT stock surged a 275.40%, with an average of 275.40% per year. If you had invested right after ECYT's IPO a $1,000 in Endocyte stock in 2018, it would worth $2,754.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Endocyte stock historical price chart

ECYT stock reached all-time highs on December with a price of $24.00.

Endocyte stock price target

How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we have not detected any price prediction for Endocyte stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

On November, Endocyte reported its latest financial data, posting a decent climb for the Earnings per Share (EPS). Analyst were expecting $-0.16 per share, but Endocyte posted $-0.17.
ECYT earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2016, last anual revenues report draw a neutral movement of 0.00% to $0.07 million dollars. By contrast, its earnings margin (compared to sales) collapsed to -78,663.14%, that is $-55.06 million.

To have an up to date view of the financial situation of Endocyte, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2018-Q3 that can be compared to 2017 fiscal year results. Annual Endocyte TTM sales up to September 2018 were $0.13 and income was $-41.34 million USD. When comparing this TTM figures with the last reported annuality, we can review Endocyte business evolution since December 2017: Annual sales up to September, compared to lastest yearly report, rocketed an astounding 83.82%. Aligned with this, profit margin (net income/sales) climbed at -78,663.14%.

ECYT annual Sales and Income evolution
2013$65 M-$-18.03 M-27.8%-
2014$70 M8.45%$5.46 M7.8%-130.28%
2015$0.07 M-99.90%$-41.27 M-58956.7%-855.93%
2016$0.07 M0.00%$-43.89 M-62696.6%6.34%
2017$0.07 M0.00%$-55.06 M-78663.1%25.47%
TTM $0.13 M83.82%$-41.34 M-32126.5%-24.93%

Quarterly financial results

Endocyte posted $0.09 M in sales for 2018-Q3, a 493.54% up compared to previous quarter. Reported quarter earnings marked $-12.61 million with a profit margin of -14,684.64%. Profit margin rocketed a 65,264.20% compared to previous quarter when profit margin was -79,948.84%. When comparing revenues to same quarter last year, Endocyte sales marked a dazzling gain and climbed a 164.17%.
ECYT quarterly Sales and Income evolution
2016-Q4$0.01 M-$-11.07 M-92250.0%-
2017-Q1$0.01 M4.17%$-11.49 M-91920.0%3.79%
2017-Q2$0.01 M0.00%$-11.74 M-93920.0%2.18%
2017-Q3$0.03 M160.00%$-23.27 M-71590.2%98.18%
2017-Q4$0.01 M-61.54%$-8.56 M-68512.2%-63.19%
2018-Q1$0.02 M26.84%$-8.60 M-54258.3%0.45%
2018-Q2$0.01 M-8.77%$-11.56 M-79948.8%34.43%
2018-Q3$0.09 M493.54%$-12.61 M-14684.6%9.02%

Endocyte ownership

When you are planning to invest in shares of a stock, it's worth to check its ownership structure.

Endocyte shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a of all shares.

The following table compares ownership indicators for other stocks related to Endocyte:

Market cap$0.0 M
Total shares0.0 M
Float shares0.0 M
  - Institutional holdings (%)0.0%
  - Insider holdings (%)0.0%
Shares in short selling0.0%

Endocyte summary

Thursday, December 20th, 2018
Day range$23.99 - $24.00
Previous close$24.00
Session gain-0.04%
Average true range$0.09
50d mov avg$22.67
100d mov avg$20.08
200d mov avg$0.00
Daily patternlb02c
Weekly pattern lt06a

Endocyte performance

To better understand Endocyte performance you must becnhmark its gains with other related stocks in same sector or industry. We compared Endocyte against in the following table:

Endocyte competitors

Unfortunately, we could not find any public company that could be defined as Endocyte competitor. This doesn't mean Endocyte does not have any competitor in the market, it's just we could not detected it.